Synthetically Engineered Adeno-Associated Virus for Efficient, Safe, and Versatile Gene Therapy Applications

Area of Science:

• Biotechnology
• Molecular Biology
• Gene Therapy

Background:

• Adeno-associated virus (AAV) vectors are increasingly utilized for gene delivery due to their safety and efficacy.
• Recent FDA approvals highlight the therapeutic potential of AAV vectors for rare genetic disorders.
• Systemic delivery of AAV vectors is challenged by pre-existing neutralizing antibodies (nAbs).

Purpose of the Study:

• To review the benefits of native adeno-associated virus (AAV) vectors for gene therapy.
• To explore the advancements and advantages of engineered AAV vectors, focusing on synthetic modifications.
• To discuss the clinical translation status of AAV-based gene therapies.

Main Methods:

• Review of existing literature on native and engineered AAV vectors.
• Analysis of strategies to overcome neutralizing antibodies (nAbs) in AAV gene therapy.
• Examination of AAV vector applications in various diseases and their clinical progression.

Main Results:

• AAV vectors offer targeted treatment at a molecular level for genetic diseases.
• Engineered AAV vectors demonstrate enhanced capabilities, including immune evasion and multimodal therapy.
• AAV vectors are being investigated for treating spinal muscular atrophy, retinal diseases, cancers, and tissue damage.

Conclusions:

• AAV vectors are a promising platform for gene therapy, with significant potential for treating a wide range of diseases.
• Engineered AAV vectors represent a significant advancement, addressing limitations of native vectors and expanding therapeutic possibilities.
• The clinical translation of AAV-based therapies is progressing, with ongoing research focused on optimizing delivery and efficacy.